In this interactive, on-demand Webcast, experts share recent developments in the care of patients with HER2-positive metastatic breast cancer, including novel therapeutic agents and strategies utilizing new antibody–drug conjugates and tyrosine kinase inhibitors after failure of standard-of-care treatments.
How confident are you in managing patients who experience interstitial lung disease while receiving trastuzumab deruxtecan?
Read expert answers to audience questions from a CCO Webinar on current best practices and emerging options for patients with HER2-positive MBC.
Download this slideset on the new and emerging antibody drug conjugates for HER2-postive MBC.
Download this slideset on newer TKIs for relapsed or refractory HER2-positive metastatic breast cancer.
Download this slideset covering a novel HER2-targeted antibody and case discussions for managing progressive HER2-positive MBC with new therapies.
Download this short summary slideset of key takeaway points from a live presentation on the novel therapies for relapsed or refractory HER2-postivie metastatic breast cancer.
Listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss 2 real-world cases of patients with HER2-positive MBC and clinical considerations in the evolving state-of-the-art care treatment landscape.